| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H26N2O2 |
| Molecular Weight | 278.3898 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1
InChI
InChIKey=GRHBODILPPXVKN-UHFFFAOYSA-N
InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
| Molecular Formula | C16H26N2O2 |
| Molecular Weight | 278.3898 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Evenamide (NW-3509) is a blocker of voltage-gated sodium channels. Evenamide modulates sustained repetitive firing, without inducing impairment of normal neuronal excitability. It normalizes glutamate release induced by aberrant sodium channel activity. The potential benefits of the compound have been demonstrated in numerous preclinical models predictive of efficacy in psychiatric diseases, including models of psychosis such as amphetamine-induced hyperactivity, sensorimotor gating and information processing deficits (pre-pulse inhibition impairment induced by different stimuli), mania and depression. Evenamide is being evaluated in a Phase II trial as add-on treatment to 5HT2/D2 blocking antipsychotics in schizophrenic patients.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.4 µM [Ki] |
Patents
Sample Use Guides
a Phase II, 4-week, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics of single and multiple doses, and preliminary evidence of efficacy of a dose range (15 mg-20mg-25mg BID) of Evenamide (NW-3509) or placebo, in the US and India, in 90 schizophrenic patients currently on risperidone (2 mg/day or higher) or aripiprazole (10 mg/day or higher) who are still symptomatic, despite at least 4 weeks of treatment at a stable dose.
Route of Administration:
Oral
